Biological Physics, Department of Physics and Astronomy, Schuster Building, Faculty of Science and Engineering, University of Manchester, M13 9PL, UK.
Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Oxford Road, Manchester M13 9PT, UK.
J Ind Microbiol Biotechnol. 2022 Jan 20;49(1). doi: 10.1093/jimb/kuab074.
The control of microorganisms is a key objective in disease prevention and in medical, industrial, domestic, and food-production environments. Whilst the effectiveness of biocides in these contexts is well-evidenced, debate continues about the resistance risks associated with their use. This has driven an increased regulatory burden, which in turn could result in a reduction of both the deployment of current biocides and the development of new compounds and formulas. Efforts to balance risk and benefit are therefore of critical importance and should be underpinned by realistic methods and a multi-disciplinary approach, and through objective and critical analyses of the literature. The current literature on this topic can be difficult to navigate. Much of the evidence for potential issues of resistance generation by biocides is based on either correlation analysis of isolated bacteria, where reports of treatment failure are generally uncommon, or laboratory studies that do not necessarily represent real biocide applications. This is complicated by inconsistencies in the definition of the term resistance. Similar uncertainties also apply to cross-resistance between biocides and antibiotics. Risk assessment studies that can better inform practice are required. The resulting knowledge can be utilised by multiple stakeholders including those tasked with new product development, regulatory authorities, clinical practitioners, and the public. This review considers current evidence for resistance and cross-resistance and outlines efforts to increase realism in risk assessment. This is done in the background of the discussion of the mode of application of biocides and the demonstrable benefits as well as the potential risks.
控制微生物是预防疾病以及医疗、工业、家庭和食品生产环境中的关键目标。虽然消毒剂在这些情况下的有效性已得到充分证明,但关于其使用相关的耐药风险的争论仍在继续。这导致监管负担增加,反过来又可能导致当前消毒剂的使用减少以及新化合物和配方的开发减少。因此,平衡风险和收益的努力至关重要,应该以现实的方法和多学科方法为基础,并通过对文献的客观和批判性分析。关于这个主题的当前文献可能难以理解。消毒剂产生耐药性的潜在问题的大部分证据要么基于孤立细菌的相关分析,在这种情况下,治疗失败的报告通常很少见,要么基于实验室研究,这些研究不一定代表真正的消毒剂应用。这使得术语“耐药性”的定义不一致更加复杂。消毒剂和抗生素之间的交叉耐药性也存在类似的不确定性。需要进行能够更好地为实践提供信息的风险评估研究。由此产生的知识可以被包括新产品开发人员、监管机构、临床医生和公众在内的多个利益相关者利用。这篇综述考虑了目前关于耐药性和交叉耐药性的证据,并概述了在风险评估中增加现实性的努力。这是在讨论消毒剂的应用方式以及可证明的益处和潜在风险的背景下进行的。